News

201 to 210 of 97511 results

Actavis’ Namenda appeal expedited to February

Actavis’ Namenda appeal expedited to February

07-01-2015

Ireland-headquartered generics major Actavis has had its motion to expedite its appeal of a lower court…

ActavisAppellate reviewLawLegalNamendaNeurologicalPharmaceuticalUSA

Cytos out-licenses VLP platform for hep B infections to OnCore Biopharma

06-01-2015

Switzerland-based Cytos Biotechnology has executed an exclusive license agreement granting privately-held…

Anti-viralsBiotechnologyCytos BiotechnologyLicensingOnCore BioPharma

23andMe and Genentech in deal to analyze genomic data for Parkinson's disease

06-01-2015

23andMe, the leading personal genetics company, and Genentech, a subsidiary of Swiss pharma giant Roche,…

23andMeBiotechnologyGenentechNeurologicalResearchRoche

Asia-Pacific type 2 diabetes market to hit $10.5 billion by 2020

06-01-2015

The type 2 diabetes treatment market in Asia-Pacific (APAC) region will rise in value from an estimated…

Asia-PacificChinaDiabetesIndiaMarkets & MarketingmetforminPharmaceutical

Columbia Labs appoints Bridget Martell to newly-created chief medical officer position

Columbia Labs appoints Bridget Martell to newly-created chief medical officer position

06-01-2015

Women’s health specialist Columbia Laboratories has appointed Bridget Martell to the newly-created…

BoardroomBridget MartellCOL-1077Columbia LaboratoriesPharmaceuticalWomen's Health

Overall safety of measles-mumps-rubella-varicella vaccine confirmed by 12-year study

Overall safety of measles-mumps-rubella-varicella vaccine confirmed by 12-year study

06-01-2015

A 12-year study published in the journal Pediatrics has confirmed the safety of two measles-containing…

MedicinePharmaceuticalResearchVaccine Study CenterVaccines

Cardio3 BioSciences acquires Celdara’s OnCyte division

Cardio3 BioSciences acquires Celdara’s OnCyte division

06-01-2015

Belgian biotech firmCardio3 BioSciences has acquired OnCyte, the oncology division of privately-held…

BiotechnologyCardio3 BioSciencesCeldara MedicalMergers & AcquisitionsOncologyOnCyte

CVS to cover Gilead’s hepatitis C drugs Harvoni and Sovaldi exclusively

CVS to cover Gilead’s hepatitis C drugs Harvoni and Sovaldi exclusively

06-01-2015

US pharmacy benefits manager CVS Health has entered into a deal with US biotech major Gilead Sciences…

GileadHarvoniNephrology and HepatologyPharmaceuticalPricingSovaldiUSA

201 to 210 of 97511 results

Back to top